These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 30945830)

  • 1. [Loss is gain? Discarding TNF-α inhibitors].
    Versteegh MM; Attema AE; Uyl-de Groot CA
    Ned Tijdschr Geneeskd; 2019 Mar; 163():. PubMed ID: 30945830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis.
    Huoponen S; Aaltonen KJ; Viikinkoski J; Rutanen J; Relas H; Taimen K; Puolakka K; Nordström D; Blom M
    PLoS One; 2019; 14(7):e0220142. PubMed ID: 31339961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Markov Analysis of Screening for Late-Onset Cytomegalovirus Disease in Cytomegalovirus High-Risk Kidney Transplant Recipients.
    Puttarajappa CM; Hariharan S; Smith KJ
    Clin J Am Soc Nephrol; 2018 Feb; 13(2):290-298. PubMed ID: 29025787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is there a kink in consumers' threshold value for cost-effectiveness in health care?
    O'Brien BJ; Gertsen K; Willan AR; Faulkner LA
    Health Econ; 2002 Mar; 11(2):175-80. PubMed ID: 11921315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability.
    Barbieri M; Drummond M; Willke R; Chancellor J; Jolain B; Towse A
    Value Health; 2005; 8(1):10-23. PubMed ID: 15841890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease Activity: Results From a Pragmatic Open-Label Trial.
    Tran-Duy A; Ghiti Moghadam M; Oude Voshaar MAH; Vonkeman HE; Boonen A; Clarke P; McColl G; Ten Klooster PM; Zijlstra TR; Lems WF; Riyazi N; Griep EN; Hazes JMW; Landewé R; Bernelot Moens HJ; van Riel PLCM; van de Laar MAFJ; Jansen TL;
    Arthritis Rheumatol; 2018 Oct; 70(10):1557-1564. PubMed ID: 29745059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-utility analysis from a societal perspective.
    Johannesson M; O'Conor RM
    Health Policy; 1997 Mar; 39(3):241-53. PubMed ID: 10165464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of TNF-Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF-Blocker Injections in Rheumatoid Arthritis Trial.
    Vanier A; Mariette X; Tubach F; Fautrel B;
    Value Health; 2017 Apr; 20(4):577-585. PubMed ID: 28407999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does willingness to pay per quality-adjusted life year bring us closer to a useful decision rule for cost-effectiveness analysis?
    Polsky D
    Med Decis Making; 2005; 25(6):605-6. PubMed ID: 16282209
    [No Abstract]   [Full Text] [Related]  

  • 10. Using value of information methods to determine the optimal sample size for effectiveness trials of alcohol interventions for HIV-infected patients in East Africa.
    Li L; Uyei J; Nucifora KA; Kessler J; Stevens ER; Bryant K; Braithwaite RS
    BMC Health Serv Res; 2018 Jul; 18(1):590. PubMed ID: 30064428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond QALYs: Multi-criteria based estimation of maximum willingness to pay for health technologies.
    Nord E
    Eur J Health Econ; 2018 Mar; 19(2):267-275. PubMed ID: 28258399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review of studies eliciting willingness-to-pay per quality-adjusted life year: does it justify CE threshold?
    Nimdet K; Chaiyakunapruk N; Vichansavakul K; Ngorsuraches S
    PLoS One; 2015; 10(4):e0122760. PubMed ID: 25855971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-utility analysis of telephone-based cognitive behavior therapy in chronic obstructive pulmonary disease (COPD) patients with anxiety and depression comorbidities: an application for willingness to accept concept.
    Moayeri F; Dunt D; Hsueh YA; Doyle C
    Expert Rev Pharmacoecon Outcomes Res; 2019 Jun; 19(3):331-340. PubMed ID: 30324818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Willingness to pay per quality-adjusted life year: is one threshold enough for decision-making?: results from a study in patients with chronic prostatitis.
    Zhao FL; Yue M; Yang H; Wang T; Wu JH; Li SC
    Med Care; 2011 Mar; 49(3):267-72. PubMed ID: 21224742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of Price Changes of Existing Tumor Necrosis Factor Inhibitors After the Market Entry of Competitors.
    San-Juan-Rodriguez A; Prokopovich MV; Shrank WH; Good CB; Hernandez I
    JAMA Intern Med; 2019 May; 179(5):713-716. PubMed ID: 30776053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Societal value of stem cell therapy in stroke--a modeling study.
    Svensson J; Ghatnekar O; Lindgren A; Lindvall O; Norrving B; Persson U; Kokaia Z
    Cerebrovasc Dis; 2012; 33(6):532-9. PubMed ID: 22571941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cost per responder analysis of secukinumab vs adalimumab for the treatment of ankylosing spondylitis from the Korean perspective.
    Kim D; Kim H; Cho S; Park MC
    Int J Rheum Dis; 2019 Sep; 22(9):1630-1637. PubMed ID: 31215166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with golimumab or infliximab reduces health resource utilization and increases work productivity in patients with ankylosing spondylitis in the QUO-VADIS study, a large, prospective real-life cohort.
    Claudepierre P; Van den Bosch F; Sarzi-Puttini P; Vastesaeger N; Govoni M; Kachroo S
    Int J Rheum Dis; 2019 Jun; 22(6):995-1001. PubMed ID: 30989813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incorporating sign-dependence in health-related social welfare functions.
    Attema AE
    Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):223-8. PubMed ID: 25543906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.